Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Short Interest Report for October

Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 9,659,086 shares, a growth of 46.4% from the October 15th total of 6,598,711 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 7,815,853 shares, the days-to-cover ratio is presently 1.2 days.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. New Street Research set a $43.00 price target on shares of Genmab A/S in a report on Wednesday, July 22nd. Morgan Stanley cut their price objective on shares of Genmab A/S from $57.00 to $56.00 and set an “equal weight” rating for the company in a research report on Friday. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday, October 26th. Guggenheim upped their target price on shares of Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Finally, Weiss Ratings upgraded shares of Genmab A/S from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $53.50.

View Our Latest Analysis on Genmab A/S

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently bought and sold shares of GMAB. First Trust Advisors LP boosted its position in Genmab A/S by 84.3% during the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock valued at $66,038,000 after buying an additional 1,126,069 shares during the period. Renaissance Technologies LLC grew its holdings in Genmab A/S by 26.4% in the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock worth $118,442,000 after acquiring an additional 921,700 shares during the last quarter. Great Point Partners LLC bought a new stake in Genmab A/S in the 3rd quarter worth $18,729,000. Marshall Wace LLP increased its position in shares of Genmab A/S by 47.0% in the third quarter. Marshall Wace LLP now owns 1,219,998 shares of the company’s stock valued at $43,517,000 after acquiring an additional 390,339 shares during the period. Finally, HighVista Strategies LLC purchased a new position in shares of Genmab A/S in the third quarter valued at about $8,066,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

NASDAQ:GMAB traded up $0.39 during trading hours on Tuesday, hitting $51.96. 3,322,111 shares of the company’s stock traded hands, compared to its average volume of 2,577,254. The firm has a market cap of $32.43 billion, a P/E ratio of 44.41, a P/E/G ratio of 2.08 and a beta of 0.73. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $59.97. The business’s fifty day simple moving average is $41.51 and its two-hundred day simple moving average is $31.70. The company has a quick ratio of 2.43, a current ratio of 2.45 and a debt-to-equity ratio of 0.74.

Genmab A/S (NASDAQ:GMAB – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.36 by $0.20. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Genmab A/S had a return on equity of 13.67% and a net margin of 16.97%. On average, research analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

About Genmab A/S

(Get Free Report)

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Featured Stories

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.